D. Sahm

发表

Prevalence in the United States of aac(6′)-Ib-cr Encoding a Ciprofloxacin-Modifying Enzyme

A. Robicsek, G. Jacoby, D. Hooper, 2006, Antimicrobial Agents and Chemotherapy.

Increasing role of Staphylococcus aureus and community-acquired methicillin-resistant Staphylococcus aureus infections in the United States: a 10-year trend of replacement and expansion.

C. Hogea, C. Acosta, J. Suaya, 2011, Microbial drug resistance.

Antimicrobial resistance in key bloodstream bacterial isolates: electronic surveillance with the Surveillance Network Database--USA.

M. Marsilio, D. Sahm, G. Piazza, 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Evaluation of Current Activities of Fluoroquinolones against Gram-Negative Bacilli Using Centralized In Vitro Testing and Electronic Surveillance

J. Karlowsky, D. Sahm, I. Critchley, 2001, Antimicrobial Agents and Chemotherapy.

Susceptibility to fluoroquinolones among commonly isolated Gram-negative bacilli in 2000: TRUST and TSN data for the United States. Tracking Resistance in the United States Today. The Surveillance Network.

A. Evangelista, J. Karlowsky, D. Sahm, 2002, International journal of antimicrobial agents.

Antimicrobial activity among multidrug-resistant Streptococcus pneumoniae isolated in the United States, 2001-2005.

A. Evangelista, D. Sahm, C. Thornsberry, 2008, Postgraduate medicine.

Susceptibility of antimicrobial-resistant urinary Escherichia coli isolates to fluoroquinolones and nitrofurantoin.

J. Karlowsky, D. Sahm, Mark E. Jones, 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Global survey of Klebsiella pneumoniae major porins from ertapenem non‐susceptible isolates lacking carbapenemases

K. Kazmierczak, D. Sahm, E. Horvath, 2018, Journal of medical microbiology.

Activity of Ceftazidime-Avibactam against Extended-Spectrum- and AmpC β-Lactamase-Producing Enterobacteriaceae Collected in the INFORM Global Surveillance Study from 2012 to 2014

K. Kazmierczak, J. Karlowsky, D. Sahm, 2016, Antimicrobial Agents and Chemotherapy.

Detection and surveillance of antimicrobial resistance.

T. O'Brien, D. Sahm, 1994, Trends in microbiology.

Clonal spread of vancomycin-resistant Enterococcus faecium between patients in three hospitals in two states

M. Zervos, J. Chow, D. Shlaes, 1993, Journal of clinical microbiology.

Multiple-drug resistant enterococci: the nature of the problem and an agenda for the future.

M. Gilmore, D. Sahm, M. Huycke, 1998, Emerging infectious diseases.

Multiyear, Multinational Survey of the Incidence and Global Distribution of Metallo-β-Lactamase-Producing Enterobacteriaceae and Pseudomonas aeruginosa

K. Kazmierczak, M. Hackel, P. Bradford, 2015, Antimicrobial Agents and Chemotherapy.

Methicillin resistance in Staphylococcus aureus.

M. Gilmore, K. Lewis, H. Taber, 2002 .

Increasing prevalence of methicillin resistance in serious ocular infections caused by Staphylococcus aureus in the United States: 2000 to 2005

P. Asbell, D. Sahm, N. Brown, 2008, Journal of cataract and refractive surgery.

Surveillance of Antimicrobial Resistance among Respiratory Tract Pathogens in the United States, 1997 to 1998

D. Sahm, J. Kahn, C. Thornsberry, 1999, Drugs.

The impact of the pneumococcal conjugate vaccine on antimicrobial resistance in the United States since 1996: evidence for a significant rebound by 2007 in many classes of antibiotics.

R. Mera, D. Sahm, H. Amrine-Madsen, 2009, Microbial drug resistance.

A clinician's guide to the appropriate and accurate use of antibiotics: the Council for Appropriate and Rational Antibiotic Therapy (CARAT) criteria.

Joseph Varon, A. Amin, J. Varon, 2005, The American journal of medicine.

Rapid Automated Antimicrobial Susceptibility Testing of Streptococcus pneumoniae by Use of the bioMerieux VITEK 2

J. Jorgensen, D. Sahm, A. Barry, 2000, Journal of Clinical Microbiology.

Phenotypes of Staphylococcus aureus against Prevalent Clones and Resistant Activity of CEM-102 (Fusidic Acid) In Vitro

J. Deane, D. Sahm, P. Fernandes, 2014 .

In Vitro Activity of CEM-102 (Fusidic Acid) against Prevalent Clones and Resistant Phenotypes of Staphylococcus aureus

J. Deane, D. Sahm, P. Fernandes, 2013, Antimicrobial Agents and Chemotherapy.

Trends in Antimicrobial Resistance among Urinary Tract Infection Isolates of Escherichia coli from Female Outpatients in the United States

J. Karlowsky, D. Sahm, Mark E. Jones, 2002, Antimicrobial Agents and Chemotherapy.

Antimicrobial resistance among uropathogens that cause community-acquired urinary tract infections in women: a nationwide analysis.

W. Stamm, D. Sahm, D. Mayfield, 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Surveillance of Antimicrobial Resistance Patterns and Data for Urinary Tract Pathogens in the USA

D. Sahm, 2001 .

Prevalence of antimicrobial resistance among urinary tract pathogens isolated from female outpatients across the US in 1999.

J. Karlowsky, M. Jones, D. Sahm, 2001, International journal of antimicrobial agents.

Antimicrobial Resistance Among Escherichia coli Urinary Tract Isolates in the United States: A Current View Provided by Electronic Surveillance

J. Karlowsky, D. Sahm, D. Mayfield, 2001 .

Broader Distribution of Plasmid-Mediated Quinolone Resistance in the United States

A. Robicsek, G. Jacoby, D. Hooper, 2005, Antimicrobial Agents and Chemotherapy.

In vitro activity of ceftazidime-avibactam against Enterobacterales and Pseudomonas aeruginosa isolates collected in Latin America as part of the ATLAS global surveillance program, 2017–2019

K. Kazmierczak, J. Karlowsky, D. Sahm, 2021, The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases.

In Vitro Activity of Ceftazidime-Avibactam against Clinical Isolates of Enterobacteriaceae and Pseudomonas aeruginosa Collected in Latin American Countries: Results from the INFORM Global Surveillance Program, 2012 to 2015

K. Kazmierczak, J. Karlowsky, D. Sahm, 2018, Antimicrobial Agents and Chemotherapy.

In Vitro Activity of Aztreonam-Avibactam against Enterobacteriaceae and Pseudomonas aeruginosa Isolated by Clinical Laboratories in 40 Countries from 2012 to 2015

K. Kazmierczak, M. Hackel, P. Bradford, 2017, Antimicrobial Agents and Chemotherapy.

In Vitro Activity of Aztreonam-Avibactam against a Global Collection of Gram-Negative Pathogens from 2012 and 2013

K. Kazmierczak, P. Bradford, D. Sahm, 2015, Antimicrobial Agents and Chemotherapy.

Trends in Antimicrobial Susceptibilities among Enterobacteriaceae Isolated from Hospitalized Patients in the United States from 1998 to 2001

J. Karlowsky, D. Sahm, Mark E. Jones, 2003, Antimicrobial Agents and Chemotherapy.

Ceftazidime-Resistant Klebsiella pneumoniae and Escherichia coli Isolates Producing TEM-10 and TEM-43 β-Lactamases from St. Louis, Missouri

K. Bush, P. Bradford, Youjun Yang, 1998, Antimicrobial Agents and Chemotherapy.

Stable antimicrobial susceptibility rates for clinical isolates of Pseudomonas aeruginosa from the 2001-2003 tracking resistance in the United States today surveillance studies.

A. Evangelista, J. Karlowsky, D. Sahm, 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Comparison of Four Antimicrobial Susceptibility Testing Methods To Determine the In Vitro Activities of Piperacillin and Piperacillin-Tazobactam against Clinical Isolates of Enterobacteriaceae and Pseudomonas aeruginosa

J. Karlowsky, D. Sahm, Mark E. Jones, 2003, Journal of Clinical Microbiology.

Prevalence of Single Mutations in Topoisomerase Type II Genes among Levofloxacin-Susceptible Clinical Strains of Streptococcus pneumoniae Isolated in the United States in 1992 to 1996 and 1999 to 2000

K. Bush, A. Evangelista, D. Sahm, 2002, Antimicrobial Agents and Chemotherapy.

Geographically-based evaluation of multidrug resistance trends among Streptococcus pneumoniae in the USA: findings of the FAST surveillance initiative (2003-2004).

G. Tillotson, M. Jones, D. Sahm, 2006, International journal of antimicrobial agents.

Susceptibility patterns and ESBL rates of Escherichia coli from urinary tract infections in Canada and the United States, SMART 2010-2014.

K. Kazmierczak, L. Nicolle, D. Hoban, 2016, Diagnostic microbiology and infectious disease.

Nosocomial outbreak of gastroenteritis due to Salmonella senftenberg.

V. Fraser, D. Murphy, D. Sahm, 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Cross-resistance, relatedness and allele analysis of fluoroquinolone-resistant US clinical isolates of Streptococcus pneumoniae (1998-2000).

K. Bush, A. Evangelista, D. Sahm, 2003, The Journal of antimicrobial chemotherapy.

Clinical Isolates of Streptococcus pneumoniae with Different Susceptibilities to Ceftriaxone and Cefotaxime

J. Karlowsky, D. Sahm, Mark E. Jones, 2003, Antimicrobial Agents and Chemotherapy.

Molecular Characterization of Vancomycin-Resistant Enterococci Repopulating the Gastrointestinal Tract following Treatment with a Novel Glycolipodepsipeptide, Ramoplanin

G. Eliopoulos, S. Porter, R. Moellering, 2002, Journal of Clinical Microbiology.

Longitudinal Assessment of Antipneumococcal Susceptibility in the United States

J. Karlowsky, D. Sahm, I. Critchley, 2002, Antimicrobial Agents and Chemotherapy.

Need for Annual Surveillance of Antimicrobial Resistance in Streptococcus pneumoniae in the United States: 2-Year Longitudinal Analysis

J. Karlowsky, D. Sahm, I. Critchley, 2001, Antimicrobial Agents and Chemotherapy.

Benchmarking the In Vitro Activities of Moxifloxacin and Comparator Agents against Recent Respiratory Isolates from 377 Medical Centers throughout the United States

D. Sahm, I. Critchley, Mark E. Jones, 2000, Antimicrobial Agents and Chemotherapy.

Benchmarking the in vitro activity of moxifloxacin against recent isolates of Streptococcus pneumoniae, Moraxella catarrhalis, and Haemophilus influenzae. A European multi-centre study.

M. Jones, D. Sahm, I. Critchley, 2000, Diagnostic microbiology and infectious disease.

A New High-Level Gentamicin Resistance Gene,aph(2")-Id, in Enterococcus spp

M. Zervos, J. Chow, D. Clewell, 1998, Antimicrobial Agents and Chemotherapy.

Use of vancomycin as a surrogate for dalbavancin in vitro susceptibility testing: results from the DISCOVER studies

D. Sahm, M. Dunne, S. Puttagunta, 2015, Annals of Clinical Microbiology and Antimicrobials.

Predominance of 23S rRNA Mutants among Non-Erm, Non-Mef Macrolide-Resistant Clinical Isolates of Streptococcus pneumoniae Collected in the United States in 1999-2000

K. Bush, A. Evangelista, D. Sahm, 2005, Antimicrobial Agents and Chemotherapy.

Antimicrobial susceptibility to levofloxacin and other antibacterial agents among common respiratory pathogens-a Brazilian perspective from the GLOBAL Surveillance Initiative 2001-2002.

J. Karlowsky, M. Jones, D. Sahm, 2004, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Tracking the implementation of NCCLS M100-S12 expanded-spectrum cephalosporin MIC breakpoints for nonmeningeal isolates of Streptococcus pneumoniae by clinical laboratories in the United States during 2002 and 2003

J. Karlowsky, D. Sahm, Mark E. Jones, 2004, Annals of Clinical Microbiology and Antimicrobials.

In Vitro Activities of Novel Nonfluorinated Quinolones PGE 9262932 and PGE 9509924 against Clinical Isolates of Staphylococcus aureus and Streptococcus pneumoniae with Defined Mutations in DNA Gyrase and Topoisomerase IV

J. Karlowsky, D. Sahm, I. Critchley, 2002, Antimicrobial Agents and Chemotherapy.

In Vitro Susceptibility of Gram-Negative Pathogens to Cefiderocol in Five Consecutive Annual Multinational SIDERO-WT Surveillance Studies, 2014 to 2019

M. Hackel, J. Karlowsky, R. Echols, 2021, Antimicrobial agents and chemotherapy.

In Vitro Activity of Ceftibuten/VNRX-5236 against Urinary Tract Infection Isolates of Antimicrobial-Resistant Enterobacterales

M. Hackel, J. Karlowsky, D. Sahm, 2021, Antimicrobial agents and chemotherapy.

In Vitro Activity of Gepotidacin against Gram-Negative and Gram-Positive Anaerobes

M. Hackel, J. Karlowsky, D. Sahm, 2021, Antimicrobial agents and chemotherapy.

Activity of ceftolozane/tazobactam against Gram-negative isolates from patients with lower respiratory tract infections – SMART United States 2018–2019

M. Motyl, J. Karlowsky, D. Sahm, 2021, BMC Microbiology.

Ceftolozane/Tazobactam and Imipenem/Relebactam Cross-Susceptibility Among Clinical Isolates of Pseudomonas aeruginosa From Patients With Respiratory Tract Infections in ICU and Non-ICU Wards—SMART United States 2017–2019

K. Kazmierczak, M. Motyl, D. Sahm, 2021, Open forum infectious diseases.

In vitro activity of ceftazidime/avibactam against clinical isolates of Enterobacterales and Pseudomonas aeruginosa from Middle Eastern and African countries: ATLAS global surveillance programme 2015–18

J. Karlowsky, D. Sahm, S. Bouchillon, 2021, JAC-antimicrobial resistance.

In Vitro Activity of WCK 5222 (Cefepime-Zidebactam) against Worldwide Collected Gram-Negative Bacilli Not Susceptible to Carbapenems

M. Hackel, J. Karlowsky, D. Sahm, 2020, Antimicrobial Agents and Chemotherapy.

Escherichia coli strains possessing a four amino acid YRIN insertion in PBP3 identified as part of the SIDERO-WT-2014 surveillance study

K. Kazmierczak, M. Hackel, D. Sahm, 2020, JAC-antimicrobial resistance.

Predicting Antibiotic Resistance in Gram-Negative Bacilli from Resistance Genes

G. Walker, M. Motyl, D. Sahm, 2019, Antimicrobial Agents and Chemotherapy.

Analysis of Potential β-Lactam Surrogates To Predict In Vitro Susceptibility and Resistance to Ceftaroline for Clinical Isolates of Enterobacteriaceae

M. Hackel, J. Karlowsky, D. Sahm, 2018, Journal of Clinical Microbiology.

In Vitro Activity of the Siderophore Cephalosporin, Cefiderocol, against Carbapenem-Nonsusceptible and Multidrug-Resistant Isolates of Gram-Negative Bacilli Collected Worldwide in 2014 to 2016

M. Hackel, J. Karlowsky, R. Echols, 2017, Antimicrobial Agents and Chemotherapy.

Resistance among Gram-negative ESKAPE pathogens isolated from hospitalized patients with intra-abdominal and urinary tract infections in Latin American countries: SMART 2013–2015

M. Hackel, J. Karlowsky, D. Hoban, 2017, The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases.

Determination of Disk Diffusion and MIC Quality Control Ranges for Nafithromycin (WCK 4873), a New Lactone-Ketolide

M. Hackel, J. Karlowsky, D. Dressel, 2017, Journal of Clinical Microbiology.

In Vitro Activity of Imipenem-Relebactam against Gram-Negative ESKAPE Pathogens Isolated by Clinical Laboratories in the United States in 2015 (Results from the SMART Global Surveillance Program)

K. Kazmierczak, M. Hackel, M. Motyl, 2017, Antimicrobial Agents and Chemotherapy.

In Vitro Activity of the Siderophore Cephalosporin, Cefiderocol, against a Recent Collection of Clinically Relevant Gram-Negative Bacilli from North America and Europe, Including Carbapenem-Nonsusceptible Isolates (SIDERO-WT-2014 Study)

M. Hackel, J. Karlowsky, R. Echols, 2017, Antimicrobial Agents and Chemotherapy.

In Vitro Activity of Imipenem against Carbapenemase-Positive Enterobacteriaceae Isolates Collected by the SMART Global Surveillance Program from 2008 to 2014

K. Kazmierczak, M. Motyl, J. Karlowsky, 2017, Journal of Clinical Microbiology.

In Vitro Activity of Meropenem-Vaborbactam against Clinical Isolates of KPC-Positive Enterobacteriaceae

M. Hackel, J. Karlowsky, M. Dudley, 2017, Antimicrobial Agents and Chemotherapy.

In Vitro Activity of Gepotidacin, a Novel Triazaacenaphthylene Bacterial Topoisomerase Inhibitor, against a Broad Spectrum of Bacterial Pathogens

M. Hackel, D. Sahm, L. Miller, 2016, Antimicrobial Agents and Chemotherapy.

Prevalence of Acinetobacter spp. isolates with reduced susceptibility to imipenem, as determined by a USA-wide electronic surveillance network.

D. Livermore, M. Jones, D. Sahm, 1999, The Journal of antimicrobial chemotherapy.

658

M. Motyl, D. Sahm, K. Young, 2019, Critical Care Medicine.

Impact of Variations in Test Method Parameters on In Vitro Activity of Surotomycin against Clostridium difficile and Surotomycin Quality Control Limits for Broth Microdilution and Agar Dilution Susceptibility Testing

Steven D. Brown, J. Deane, D. Sahm, 2015, Journal of Clinical Microbiology.

Antibiotic resistance - is resistance detected by surveillance relevant to predicting resistance in the clinical setting?

J. Karlowsky, D. Sahm, 2002, Current opinion in pharmacology.

Information technology: A means for enhancing surveillance of antimicrobial resistance

D. Sahm, 1999 .

In Vitro Activity of Tigecycline against Gram-Positive and Gram-Negative Pathogens as Evaluated by Broth Microdilution and Etest

D. Sahm, Deborah C. Draghi, M. Dowzicky, 2008, Journal of Clinical Microbiology.

In Vitro Activity of Doripenem, a Carbapenem for the Treatment of Challenging Infections Caused by Gram-Negative Bacteria, against Recent Clinical Isolates from the United States

D. Sahm, N. Brown, C. Pillar, 2008, Antimicrobial Agents and Chemotherapy.

In Vitro Profiling of Ceftaroline against a Collection of Recent Bacterial Clinical Isolates from across the United States

G. Talbot, D. Sahm, D. Biek, 2008, Antimicrobial Agents and Chemotherapy.

Methicillin resistance in Staphylococcus aureus.

M. Gilmore, K. Lewis, H. Taber, 2002 .

Prevalence and antimicrobial susceptibilities of bacteria isolated from blood cultures of hospitalized patients in the United States in 2002

J. Karlowsky, D. Sahm, Mark E. Jones, 2004, Annals of Clinical Microbiology and Antimicrobials.

In Vitro Susceptibilities of Gram-Negative Bacteria Isolated from Hospitalized Patients in Four European Countries, Canada, and the United States in 2000-2001 to Expanded-Spectrum Cephalosporins and Comparator Antimicrobials: Implications for Therapy

R. Wenzel, J. Karlowsky, D. Sahm, 2003, Antimicrobial Agents and Chemotherapy.

Survey of Susceptibilities of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis Isolates to 26 Antimicrobial Agents: a Prospective U.S. Study

D. Sahm, C. Thornsberry, H. Holley, 1999, Antimicrobial Agents and Chemotherapy.

In Vitro Susceptibility to Ceftazidime-Avibactam of Carbapenem-Nonsusceptible Enterobacteriaceae Isolates Collected during the INFORM Global Surveillance Study (2012 to 2014)

K. Kazmierczak, J. Karlowsky, D. Sahm, 2016, Antimicrobial Agents and Chemotherapy.

Virulence characteristics and phylogenetic background of multidrug-resistant and antimicrobial-susceptible clinical isolates of Escherichia coli from across the United States, 2000-2001.

M. Kuskowski, James R. Johnson, J. Karlowsky, 2004, The Journal of infectious diseases.

Regional trends in antimicrobial resistance among clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States: results from the TRUST Surveillance Program, 1999-2000.

A. Evangelista, J. Karlowsky, D. Sahm, 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Infrequent occurrence of single mutations in topoisomerase IV and DNA gyrase genes among US levofloxacin-susceptible clinical isolates of Streptococcus pneumoniae from nine institutions (1999-2003).

K. Bush, A. Evangelista, D. Sahm, 2006, The Journal of antimicrobial chemotherapy.

Baseline Study To Determine In Vitro Activities of Daptomycin against Gram-Positive Pathogens Isolated in the United States in 2000-2001

J. Karlowsky, D. Sahm, I. Critchley, 2003, Antimicrobial Agents and Chemotherapy.

Factors associated with relative rates of antimicrobial resistance among Streptococcus pneumoniae in the United States: results from the TRUST Surveillance Program (1998-2002).

A. Evangelista, J. Karlowsky, D. Sahm, 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Activity of daptomycin against susceptible and multidrug-resistant Gram-positive pathogens collected in the SECURE study (Europe) during 2000-2001.

J. Karlowsky, D. Sahm, I. Critchley, 2003, The Journal of antimicrobial chemotherapy.

In Vitro Activities of Broad-Spectrum Cephalosporins against Nonmeningeal Isolates of Streptococcus pneumoniae: MIC Interpretation Using NCCLS M100-S12 Recommendations

J. Karlowsky, D. Sahm, Mark E. Jones, 2002, Journal of Clinical Microbiology.

Phenotypic and genotypic analysis of levofloxacin-resistant clinical isolates of Streptococcus pneumoniae collected in 13 countries during 1999-2000.

J. Karlowsky, D. Sahm, I. Critchley, 2002, International journal of antimicrobial agents.

Antimicrobial susceptibilities of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis isolated in two successive respiratory seasons in the US.

J. Karlowsky, D. Sahm, I. Critchley, 2002, International journal of antimicrobial agents.

Levofloxacin-Resistant Streptococcus pneumoniae: Second Look

J. Karlowsky, D. Sahm, C. Thornsberry, 2001, Antimicrobial Agents and Chemotherapy.

In vitro activity of grepafloxacin and 25 other antimicrobial agents against Streptococcus pneumoniae: correlation with penicillin resistance.

D. Sahm, C. Thornsberry, H. Holley, 1998, Clinical therapeutics.

Factors Associated with Relative Rates of Antibiotic Resistance in Pseudomonas aeruginosa Isolates Tested in Clinical Laboratories in the United States from 1999 to 2002

J. Karlowsky, D. Sahm, R. Flamm, 2004, Antimicrobial Agents and Chemotherapy.

Prevalence of mcr-type genes among colistin-resistant Enterobacteriaceae collected in 2014-2016 as part of the INFORM global surveillance program

K. Kazmierczak, D. Sahm, M. Wise, 2018, PloS one.

Ocular TRUST: nationwide antimicrobial susceptibility patterns in ocular isolates.

M. Raizman, P. Asbell, P. McDonnell, 2008, American journal of ophthalmology.

Susceptibilities to Levofloxacin in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis Clinical Isolates from Children: Results from 2000-2001 and 2001-2002 TRUST Studies in the United States

G. Noel, A. Evangelista, J. Karlowsky, 2003, Antimicrobial Agents and Chemotherapy.

Antimicrobial susceptibility of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis collected from five centers in Brazil, 1997-98.

M. Jones, D. Sahm, H. Sader, 2000, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Emerging trends in antimicrobial resistance: a laboratory perspective.

D. Sahm, Daniel F. Sahm, 1995, Advances in experimental medicine and biology.

Streptococci and staphylococci: Laboratory considerations for in vitro susceptibility testing

D. Sahm, 1994 .

Linezolid-Resistant Staphylococcus aureus Strain 1128105, the First Known Clinical Isolate Possessing the cfr Multidrug Resistance Gene

R. Goering, J. Deane, D. Sahm, 2014, Antimicrobial Agents and Chemotherapy.

Antimicrobial susceptibilities of Streptococcus pyogenes isolated from respiratory and skin and soft tissue infections: United States LIBRA surveillance data from 1999.

J. Karlowsky, D. Sahm, I. Critchley, 2002, Diagnostic microbiology and infectious disease.

Longitudinal analysis of ESBL and carbapenemase carriage among Enterobacterales and Pseudomonas aeruginosa isolates collected in Europe as part of the International Network for Optimal Resistance Monitoring (INFORM) global surveillance programme, 2013-17.

K. Kazmierczak, D. Sahm, G. Stone, 2020, The Journal of antimicrobial chemotherapy.

In vitro activity of ceftazidime/avibactam against isolates of Enterobacteriaceae collected in European countries: INFORM global surveillance 2012–15

K. Kazmierczak, D. Sahm, G. Stone, 2018, The Journal of antimicrobial chemotherapy.

Resistance in Respiratory Tract Pathogens: An International Study 1997–1998

D. Sahm, C. Thornsberry, 2000, Journal of chemotherapy.

Apparent plateau in beta-lactamase production among clinical isolates of Haemophilus influenzae and Moraxella catarrhalis in the United States: results from the LIBRA Surveillance initiative.

J. Karlowsky, D. Sahm, I. Critchley, 2002, International journal of antimicrobial agents.

Inducible and constitutive expression of vanC-1-encoded resistance to vancomycin in Enterococcus gallinarum

S. Handwerger, D. Sahm, L. Free, 1995, Antimicrobial agents and chemotherapy.

Analysis of Ciprofloxacin Activity against Streptococcus pneumoniae after 10 Years of Use in the United States

D. Sahm, I. Critchley, C. Thornsberry, 2000, Antimicrobial Agents and Chemotherapy.

Prevalence of gyrA, gyrB, parC, and parE Mutations in Clinical Isolates ofStreptococcus pneumoniae with Decreased Susceptibilities to Different Fluoroquinolones and Originating from Worldwide Surveillance Studies during the 1997-1998 Respiratory Season

K. Köhrer, P. Heisig, D. Sahm, 2000, Antimicrobial Agents and Chemotherapy.

Fluoroquinolone resistance in Streptococcus pneumoniae.

D. Sahm, D. Peterson, 1999, The New England journal of medicine.

In vitro susceptibility of recent clinical isolates of pneumococci to the investigational cephalosporin cefditoren.

J. Karlowsky, D. Sahm, I. Critchley, 2002, Diagnostic microbiology and infectious disease.

Rates of antimicrobial resistance among common bacterial pathogens causing respiratory, blood, urine, and skin and soft tissue infections in pediatric patients

J. Karlowsky, J. Bradley, M. Jones, 2004, European Journal of Clinical Microbiology and Infectious Diseases.

Antimicrobial susceptibility of 840 clinical isolates of Haemophilus influenzae collected in four European countries in 2000-2001.

J. Karlowsky, M. Jones, D. Sahm, 2003, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Relationship between Antibiotic Resistance in Streptococcus pneumoniae and That in Haemophilus influenzae: Evidence for Common Selective Pressure

J. Karlowsky, D. Sahm, I. Critchley, 2002, Antimicrobial Agents and Chemotherapy.

Effects of the 7-valent pneumococcal conjugate vaccine on U.S. levofloxacin-resistant Streptococcus pneumoniae.

K. Bush, A. Evangelista, D. Sahm, 2008, Microbial drug resistance.

Impact of new Clinical Laboratory Standards Institute Streptococcus pneumoniae penicillin susceptibility testing breakpoints on reported resistance changes over time.

R. Mera, D. Sahm, H. Amrine-Madsen, 2011, Microbial drug resistance.

Ceftriaxone activity against Gram-positive and Gram-negative pathogens isolated in US clinical microbiology laboratories from 1996 to 2000: results from The Surveillance Network (TSN) Database-USA.

J. Karlowsky, M. Jones, D. Sahm, 2002, International journal of antimicrobial agents.

Antimicrobial Resistance in Respiratory Tract Pathogens: Results of an International Surveillance Study

D. Sahm, C. Thornsberry, 2000, Chemotherapy.

The activity of levofloxacin and other antimicrobials against clinical isolates of Streptococcus pneumoniae collected worldwide during 1999-2002.

J. Karlowsky, D. Sahm, Mark E. Jones, 2003, Diagnostic microbiology and infectious disease.

Clinical and Public Health Implications of Macrolide-Resistant Streptococcus pneumoniae

T. File, J. Metlay, M. Edmond, 2002, Journal of chemotherapy.

In Vitro Activity of Ceftaroline against Staphylococcus aureus Isolated in 2012 from Asia-Pacific Countries as Part of the AWARE Surveillance Program

J. Ambler, R. Alm, D. Hoban, 2015, Antimicrobial Agents and Chemotherapy.

In Vitro Activity of Ceftaroline against Staphylococcus aureus Isolates Collected in 2012 from Latin American Countries as Part of the AWARE Surveillance Program

J. Ambler, R. Alm, D. Hoban, 2015, Antimicrobial Agents and Chemotherapy.

The vanB gene of vancomycin-resistant Enterococcus faecalis V583 is structurally related to genes encoding D-Ala:D-Ala ligases and glycopeptide-resistance proteins VanA and VanC.

P. Courvalin, D. Sahm, S. Evers, 1993, Gene.

Enteric Carriage of Vancomycin-Resistant Enterococcus faecium in Patients Tested for Clostridium difficile

B. Littenberg, B. Evanoff, D. Sahm, 1999, Infection Control & Hospital Epidemiology.

Comparison of the autoSCAN-W/A rapid bacterial identification system and the Vitek AutoMicrobic system for identification of gram-negative bacilli

D. Rhoden, M. Pfaller, D. Sahm, 1991, Journal of clinical microbiology.

Activity of Ceftolozane/Tazobactam Against Clinical Isolates of Pseudomonas aeruginosa from Patients in the Middle East and Africa - SMART 2017-2020.

M. Motyl, D. Sahm, K. Young, 2022, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

Activity of imipenem-relebactam against multidrug-resistant Pseudomonas aeruginosa from the United States - SMART 2015-2017.

M. Motyl, J. Karlowsky, D. Sahm, 2019, Diagnostic microbiology and infectious disease.

Activity of imipenem/relebactam against MDR Pseudomonas aeruginosa in Europe: SMART 2015-17.

M. Motyl, J. Karlowsky, D. Sahm, 2019, The Journal of antimicrobial chemotherapy.

In vitro activity of ceftazidime/avibactam against isolates of Pseudomonas aeruginosa collected in European countries: INFORM global surveillance 2012–15

K. Kazmierczak, D. Sahm, G. Stone, 2018, The Journal of antimicrobial chemotherapy.

In Vitro Activity of Ceftazidime-Avibactam against Clinical Isolates of Enterobacteriaceae and Pseudomonas aeruginosa Collected in Asia-Pacific Countries: Results from the INFORM Global Surveillance Program, 2012 to 2015

K. Kazmierczak, J. Karlowsky, D. Sahm, 2018, Antimicrobial Agents and Chemotherapy.

Activities of carbapenem and comparator agents against contemporary US Pseudomonas aeruginosa isolates from the CAPITAL surveillance program.

J. Deane, D. Sahm, R. Flamm, 2013, Diagnostic microbiology and infectious disease.

qnr Prevalence in Ceftazidime-Resistant Enterobacteriaceae Isolates from the United States

A. Robicsek, G. Jacoby, D. Hooper, 2006, Antimicrobial Agents and Chemotherapy.

Resistance Trends and Susceptibility Profiles in the US Among Prevalent Clinical Pathogens: Lessons from Surveillance

D. Sahm, C. Pillar, 2012 .

Missouri -Lactamases from St. Louis, β and TEM-43 TEM-10 and Escherichia coli Isolates Producing Ceftazidime-Resistant Klebsiella pneumoniae

P. Bradford, D. Sahm, N. Bhachech, 2013 .

Acinetobacter baumannii 2002-2008: increase of carbapenem-associated multiclass resistance in the United States.

R. Mera, D. Sahm, H. Amrine-Madsen, 2010, Microbial drug resistance.

Prevalence of antimicrobial resistance in bacteria isolated from central nervous system specimens as reported by U.S. hospital laboratories from 2000 to 2002

J. Karlowsky, J. Bradley, D. Sahm, 2004, Annals of Clinical Microbiology and Antimicrobials.

Invitro activity of levofloxacin against contemporary clinical isolates of Legionella pneumophila, Mycoplasma pneumoniae and Chlamydia pneumoniae from North America and Europe

A. Evangelista, J. Karlowsky, M. Jones, 2014 .

Surveillance for the emergence and dissemination of antimicrobial resistance in bacteria.

F. Tenover, D. Sahm, 1997, Infectious disease clinics of North America.

Activity of faropenem, a new furanem, against European respiratory pathogens collected during 2000-2001: a comparison with other beta-lactam agents.

J. Karlowsky, D. Sahm, I. Critchley, 2003, The Journal of antimicrobial chemotherapy.

In vitro activity of imipenem/relebactam against Gram-negative ESKAPE pathogens isolated in 17 European countries: 2015 SMART surveillance programme

K. Kazmierczak, S. Magnet, M. Motyl, 2018, The Journal of antimicrobial chemotherapy.

Molecular characterization and multilaboratory evaluation of Enterococcus faecalis ATCC 51299 for quality control of screening tests for vancomycin and high-level aminoglycoside resistance in enterococci

M. Weinstein, J. Hindler, M. Ferraro, 1995, Journal of clinical microbiology.

In vitro susceptibility and molecular analysis of gentamicin-resistant enterococci.

M. Zervos, J. Chow, D. Clewell, 1998, Diagnostic microbiology and infectious disease.

Ceftibuten-Ledaborbactam Activity against Multidrug-Resistant and Extended-Spectrum-β-Lactamase-Positive Clinical Isolates of Enterobacterales from a 2018–2020 Global Surveillance Collection

M. Hackel, J. Karlowsky, D. Sahm, 2022, Antimicrobial agents and chemotherapy.

1 AAC 01304-21 R 1 1 2 In Vitro Activity of Ceftibuten / VNRX-5236 against Urinary Tract Infection Isolates of 3 Antimicrobial-Resistant Enterobacterales 4 5

M. Hackel, J. Karlowsky, D. Sahm, 2021 .

In Vitro Activity of Imipenem/Relebactam and Ceftolozane/Tazobactam against Clinical Isolates of Gram-Negative Bacilli with Difficult-to-Treat Resistance and Multidrug-Resistant Phenotypes - SMART United States 2015-2017.

M. Motyl, J. Karlowsky, D. Sahm, 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Trends in Susceptibility of Escherichia coli from Intra-Abdominal Infections to Ertapenem and Comparators in the United States According to Data from the SMART Program, 2009 to 2013

K. Kazmierczak, M. Hackel, D. Sahm, 2015, Antimicrobial Agents and Chemotherapy.

Five-Year Longitudinal Assessment (2008 to 2012) of E-101 Solution Activity against Clinical Target and Antimicrobial-Resistant Pathogens

D. Sahm, P. O'Hanley, C. Pillar, 2014, Antimicrobial Agents and Chemotherapy.

Prevalence of multidrug-resistant, methicillin-resistant Staphylococcus aureus in the United States: findings of the stratified analysis of the 2004 to 2005 LEADER Surveillance Programs.

D. Sahm, D. Sheehan, Deborah C. Draghi, 2008, Diagnostic microbiology and infectious disease.

Emerging Plasmid-Mediated Quinolone Resistance Associated with the qnr Gene in Klebsiella pneumoniae Clinical Isolates in the United States

G. Jacoby, D. Hooper, D. Sahm, 2004, Antimicrobial Agents and Chemotherapy.

Rapid characterization schemes for surveillance isolates of vancomycin-resistant enterococci

D. Sahm, L. Mundy, M. Eveland, 1997, Journal of clinical microbiology.

Mechanisms of antimicrobial resistance

D. Sahm, 1989 .

VanE, a New Type of Acquired Glycopeptide Resistance in Enterococcus faecalis BM4405

P. Courvalin, P. Reynolds, D. Sahm, 1999, Antimicrobial Agents and Chemotherapy.

WHY ANTIMICROBIAL RESISTANCE IS A SILENT PANDEMIC

J. Schneider, D. Sahm, B. Murphy, 2021 .

Adherence of Acanthamoeba castellanii cysts and trophozoites to unworn soft contact lenses.

D. Sahm, T. John, D. Desai, 1989, American journal of ophthalmology.

Effects of corticosteroids in experimental Acanthamoeba keratitis.

D. Sahm, T. John, J. H. Rockey, 1991, Reviews of infectious diseases.

Bailey and scotts diagnostic microbiology

B. A. Forbes, A. Weissfeld, D. Sahm, 2013 .

Multidrug-Resistant Urinary Tract Isolates ofEscherichia coli: Prevalence and Patient Demographics in the United States in 2000

Clyde Thornsberry, J. Karlowsky, D. Sahm, 2001, Antimicrobial Agents and Chemotherapy.

Activities of Faropenem, an Oral β-Lactam, against Recent U.S. Isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis

J. Karlowsky, D. Sahm, I. Critchley, 2002, Antimicrobial Agents and Chemotherapy.

In vivo development of teicoplanin resistance in a VanB Enterococcus faecium isolate.

G. Trenholme, D. Sahm, M. Hayden, 1993, The Journal of infectious diseases.

Effect of Polysorbate 80 on Oritavancin Binding to Plastic Surfaces: Implications for Susceptibility Testing

D. Sahm, G. Moeck, F. Arhin, 2008, Antimicrobial Agents and Chemotherapy.

1 Effect of Polysorbate-80 on Oritavancin Binding to Plastic Surfaces – 1 Implications for Susceptibility Testing 2 3 4 Running Title : Polysorbate-80 effect on oritavancin binding 5 6 7

D. Sahm, G. Moeck, F. Arhin, 2008 .

Determining Linezolid’s Baseline In Vitro Activity in Canada Using Gram-Positive Clinical Isolates Collected prior to Its National Release

J. Karlowsky, D. Sahm, I. Critchley, 2002, Antimicrobial Agents and Chemotherapy.

Comparative In Vitro Activity Profile of Oritavancin against Recent Gram-Positive Clinical Isolates

D. Sahm, G. Moeck, F. Arhin, 2009, Antimicrobial Agents and Chemotherapy.

In vitro activity of telavancin against recent Gram-positive clinical isolates: results of the 2004-05 Prospective European Surveillance Initiative.

K. Krause, D. Sahm, C. Thornsberry, 2008, The Journal of antimicrobial chemotherapy.

Comparative Surveillance Study of Telavancin Activity against Recently Collected Gram-Positive Clinical Isolates from across the United States

K. Krause, D. Sahm, C. Thornsberry, 2008, Antimicrobial Agents and Chemotherapy.

Bactericidal Activity and Resistance Development Profiling of Dalbavancin

B. Goldstein, D. Sahm, D. Sheehan, 2007, Antimicrobial Agents and Chemotherapy.

Newly defined in vitro quality control ranges for oritavancin broth microdilution testing and impact of variation in testing parameters.

D. Sahm, G. Moeck, F. Arhin, 2008, Diagnostic microbiology and infectious disease.

Epidemiology and antibiotic susceptibility of bacteria causing skin and soft tissue infections in the USA and Europe: a guide to appropriate antimicrobial therapy.

D. Nathwani, J. Karlowsky, D. Sahm, 2003, International journal of antimicrobial agents.

Surveillance of antimicrobial resistance--what, how and whither?

V. Isham, H. Goossens, M. Struelens, 2001, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Laboratory-based surveillance of current antimicrobial resistance patterns and trends among Staphylococcus aureus: 2005 status in the United States

D. Sahm, D. Sheehan, P. Hogan, 2006, Annals of Clinical Microbiology and Antimicrobials.

In vitro Synergy Studies Using Aztreonam and Fluoroquinolone Combinations against Six Species of Gram-Negative Bacilli

J. Karlowsky, D. Sahm, I. Critchley, 2003, Chemotherapy.

Medium-dependent zone size discrepancies associated with susceptibility testing of group D streptococci against various cephalosporins

R. Jones, D. Sahm, C. Baker, 1983, Journal of clinical microbiology.

Multilaboratory evaluation of screening methods for detection of high-level aminoglycoside resistance in enterococci. National Committee for Clinical Laboratory Standards Study Group on Enterococci

M. Ferraro, F. Tenover, N. Clark, 1995, Journal of Clinical Microbiology.

High-content aminoglycoside disks for determining aminoglycoside-penicillin synergy against Enterococcus faecalis

D. Sahm, C. Torres, 1988, Journal of clinical microbiology.

Influence of growth medium on the in vitro activities of second- and third-generation cephalosporins against Streptococcus faecalis

R. Jones, D. Sahm, C. Baker, 1984, Journal of clinical microbiology.

Effect of media and blood on the antimicrobial activity of cephalosporins on serogroup D streptococci: a review.

D. Sahm, C. Thornsberry, 1984, Diagnostic microbiology and infectious disease.

Vancomycin elimination during high-flux hemodialysis: kinetic model and comparison of four membranes.

D. Sahm, J. Umans, C. A. DeSoi, 1992, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Modification of the Sceptor system for rapid detection of methicillin-resistant staphylococci

D. Sahm, D F Sahm, G A Denys, 1986, Journal of clinical microbiology.

In vitro activities of quinolones against enterococci resistant to penicillin-aminoglycoside synergy

D. Sahm, G. T. Koburov, 1989, Antimicrobial Agents and Chemotherapy.

Surveillance for Antimicrobial Susceptibility among Clinical Isolates of Pseudomonas aeruginosa and Acinetobacter baumannii from Hospitalized Patients in the United States, 1998 to 2001

J. Karlowsky, D. Sahm, Mark E. Jones, 2003, Antimicrobial Agents and Chemotherapy.

Factors influencing the vitek gram-positive susceptibility system's detection of vanB-encoded vancomycin resistance among enterococci

D. Sahm, D F Sahm, B Jett, 1996, Journal of clinical microbiology.

Investigation of the reformulated Remel Synergy Quad plate for detection of high-level aminoglycoside and vancomycin resistance among enterococci

D. Sahm, L. Free, 1995, Journal of clinical microbiology.

New vancomycin disk diffusion breakpoints for enterococci. The National Committee for Clinical Laboratory Standards Working Group on Enterococci

M. Ferraro, F. Tenover, D. Sahm, 1992, Journal of clinical microbiology.

In vitro detection of enterococcal vancomycin resistance

D. Sahm, D F Sahm, L Olsen, 1990, Antimicrobial Agents and Chemotherapy.

Controversies and confusion regarding antimicrobial susceptibility testing of enterococci

D. Sahm, J. Hindler, 1992 .

Vancomycin susceptibility and identification of motile enterococci

D. Shlaes, D. Sahm, M. Green, 1991, Journal of clinical microbiology.

Factors influencing determination of high-level aminoglycoside resistance in Enterococcus faecalis

G L Woods, P. Iwen, G. Woods, 1991, Journal of clinical microbiology.

Effects of medium and inoculum variations on screening for high-level aminoglycoside resistance in Enterococcus faecalis

D. Sahm, C. Torres, C. Torres, 1988, Journal of clinical microbiology.

Transferability and genetic relatedness of high-level gentamicin resistance among enterococci

M. Gilmore, D. Sahm, 1994, Antimicrobial Agents and Chemotherapy.

Detection of high-level aminoglycoside resistance in enterococci other than Enterococcus faecalis

D. Sahm, S. Boonlayangoor, D F Sahm, 1991, Journal of clinical microbiology.

In vitro susceptibility studies of vancomycin-resistant Enterococcus faecalis

P. Murray, M. Gilmore, D. Sahm, 1989, Antimicrobial Agents and Chemotherapy.

β-Lactam antibiotics: The first- and second-generation cephalosporins

R. Jones, D. Sahm, C. Thornsberry, 1985 .

In vitro susceptibility of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis: a European multicenter study during 2000-2001.

J. Karlowsky, M. Jones, D. Sahm, 2003, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Direct susceptibility testing of blood culture isolates with the AutoMicrobic System (AMS).

D. Sahm, S. Boonlayangoor, J. A. Morello, 1987, Diagnostic microbiology and infectious disease.

Relationships between Enterococcal Virulence and Antimicrobial Resistance

M. Gilmore, D. Sahm, L. Mundy, 2000, Clinical Microbiology Reviews.

Relationships between enterococcal virulence and antimicrobial resistance.

M. Gilmore, D. Sahm, L. Mundy, 2000, Clinical microbiology reviews.

P1676 Evaluation of isavuconazole (BAL8557/BAL4815) Etest compared to broth microdilution antifungal susceptibility testing against quality control strains and fluconazole-susceptible clinical Candida isolates

D. Sahm, M. Heep, Mark E. Jones, 2007 .

Annals of Clinical Microbiology and Antimicrobials Open Access Emerging Resistance among Bacterial Pathogens in the Intensive Care Unit – a European and North American Surveillance Study (2000–2002) Intensive-care Unitantibiotic Susceptibility

R. Wenzel, J. Karlowsky, D. Sahm, 2022 .

Trends in Antibiotic Resistance Among Ocular Microorganisms in the United States From 2009 to 2018

P. Asbell, D. Sahm, H. DeCory, 2020, JAMA ophthalmology.

Monitoring antibiotic resistance in ocular microorganisms: results from the Antibiotic Resistance Monitoring in Ocular micRorganisms (ARMOR) 2009 surveillance study.

T. Morris, D. Sahm, C. Pillar, 2011, American journal of ophthalmology.

Antibiotic Resistance Among Ocular Pathogens in the United States: Five-Year Results From the Antibiotic Resistance Monitoring in Ocular Microorganisms (ARMOR) Surveillance Study.

P. Asbell, T. Morris, D. Sahm, 2015, JAMA ophthalmology.

A Systematic Review of Multi-decade Antibiotic Resistance Data for Ocular Bacterial Pathogens in the United States

P. Asbell, D. Sahm, P. Bispo, 2022, Ophthalmology and Therapy.

Global Dissemination of blaKPC into Bacterial Species beyond Klebsiella pneumoniae and In Vitro Susceptibility to Ceftazidime-Avibactam and Aztreonam-Avibactam

K. Kazmierczak, M. Hackel, P. Bradford, 2016, Antimicrobial Agents and Chemotherapy.

Molecular Characterization of Clinical Isolates of Enterobacterales with Elevated MIC Values for Aztreonam-Avibactam from the INFORM Global Surveillance Study, 2012-2017.

K. Kazmierczak, D. Sahm, F. Arhin, 2021, Journal of global antimicrobial resistance.

Discrepancy between genotypic and phenotypic extended-spectrum β-lactamase rates in Escherichia coli from intra-abdominal infections in the USA.

K. Kazmierczak, D. Sahm, R. Badal, 2016, Journal of medical microbiology.

In Vitro Activity of Ceftazidime-Avibactam and Aztreonam-Avibactam against OXA-48-Carrying Enterobacteriaceae Isolated as Part of the International Network for Optimal Resistance Monitoring (INFORM) Global Surveillance Program from 2012 to 2015

K. Kazmierczak, P. Bradford, D. Sahm, 2018, Antimicrobial Agents and Chemotherapy.

CTX-M-5, a Novel Cefotaxime-Hydrolyzing β-Lactamase from an Outbreak of Salmonella typhimuriumin Latvia

G. Storch, P. Bradford, Youjun Yang, 1998, Antimicrobial Agents and Chemotherapy.

In Vitro Antimicrobial Activity of Doripenem, a New Carbapenem

J. Karlowsky, D. Sahm, M. Wikler, 2004, Antimicrobial Agents and Chemotherapy.

Antibiotic Resistance Surveillance of Ocular Pathogens - four years of ARMOR Study Results

T. Morris, J. Deane, D. Sahm, 2013 .

Recent trends in resistance to cell envelope–active antibacterial agents among key bacterial pathogens

J. Deane, D. Sahm, R. Master, 2013, Annals of the New York Academy of Sciences.

Tracking resistance among bacterial respiratory tract pathogens: summary of findings of the TRUST Surveillance Initiative, 2001-2005.

A. Evangelista, D. Sahm, C. Thornsberry, 2008, Postgraduate medicine.

Adherence of Acanthamoeba castellanii to new daily wear, extended wear, and disposable soft contact lenses.

D. Sahm, T. John, D. Desai, 1991, The CLAO journal : official publication of the Contact Lens Association of Ophthalmologists, Inc.

Adherence of Acanthamoeba castellanii cysts and trophozoites to extended wear soft contact lenses.

D. Sahm, T. John, D. Desai, 1991, Reviews of infectious diseases.

In vitro activity of imipenem/relebactam against piperacillin/tazobactam-resistant and meropenem-resistant non-Morganellaceae Enterobacterales and Pseudomonas aeruginosa collected from patients with bloodstream, intra-abdominal and urinary tract infections in Western Europe: SMART 2018-2020.

M. Motyl, J. Karlowsky, D. Sahm, 2023, Journal of medical microbiology.

In vitro activity of imipenem/relebactam against piperacillin/tazobactam-resistant and meropenem-resistant non-Morganellaceae Enterobacterales and Pseudomonas aeruginosa collected from patients with lower respiratory tract infections in Western Europe: SMART 2018–20

M. Motyl, J. Karlowsky, D. Sahm, 2022, JAC-antimicrobial resistance.

Carbapenem-resistant Enterobacterales and Pseudomonas aeruginosa causing infection in Africa and the Middle East: a surveillance study from the ATLAS programme (2018–20)

J. Karlowsky, D. Sahm, S. Bouchillon, 2022, JAC-antimicrobial resistance.

In vitro activity profile of ceftobiprole, an anti-MRSA cephalosporin, against recent gram-positive and gram-negative isolates of European origin.

D. Sahm, C. Pillar, D. Shah, 2008, The Journal of antimicrobial chemotherapy.

Resistance surveillance of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis isolated in Asia and Europe, 1997-1998.

M. Jones, D. Sahm, C. Thornsberry, 2000, The Journal of antimicrobial chemotherapy.

Resistance surveillance of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis isolated in the United States, 1997-1998.

M. Jones, D. Sahm, Mark E. Jones, 1999, The Journal of antimicrobial chemotherapy.

Comparative Activity of Cefditoren and Other Oral β-Lactams against Nonpneumococcal Streptococci

J. Karlowsky, D. Sahm, I. Critchley, 2001, Chemotherapy.

Development of a standardized screening method for detection of vancomycin-resistant enterococci

M. Weinstein, M. Ferraro, F. Tenover, 1994, Journal of clinical microbiology.

Organisms associated with Gram-negative folliculitis: In vitro growth in the presence of isotretinoin

K. Soltani, D. Sahm, J. A. Morello, 2004, Archives of Dermatological Research.

Pooled analysis of single-dose oritavancin in the treatment of acute bacterial skin and skin-structure infections caused by Gram-positive pathogens, including a large patient subset with methicillin-resistant Staphylococcus aureus.

B. Kreiswirth, W. O'Riordan, D. Sahm, 2016, International journal of antimicrobial agents.

Epidemiology of Carbapenem Resistance Determinants Identified in Meropenem-Nonsusceptible Enterobacterales Collected as Part of a Global Surveillance Program, 2012 to 2017

K. Kazmierczak, J. Karlowsky, D. Sahm, 2021, Antimicrobial agents and chemotherapy.

Multidrug resistance among Acinetobacter spp. in the USA and activity profile of key agents: results from CAPITAL Surveillance 2010.

J. Deane, D. Sahm, R. Flamm, 2012, Diagnostic microbiology and infectious disease.

Regional differences and trends in antimicrobial susceptibility of Acinetobacter baumannii.

D. Hoban, D. Sahm, R. Badal, 2016, International journal of antimicrobial agents.

In vitro activity of doripenem.

D. Sahm, 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

In vitro activity of imipenem-relebactam and key β-lactam agents against Gram-negative bacilli isolated from lower respiratory tract infection samples of intensive care unit patients - SMART Surveillance United States 2015-2017.

K. Kazmierczak, M. Motyl, J. Karlowsky, 2019, International journal of antimicrobial agents.

Gamma‐glutamyltranspeptidase levels as an aid in the management of human cancer

R. Nordquist, D. Sahm, M. Lerner, 1983, Cancer.

Antimicrobial Surveillance of Haemophilus influenzae in the United States during 2000-2001 Leads to Detection of Clonal Dissemination of a β-Lactamase-Negative and Ampicillin-Resistant Strain

J. Karlowsky, D. Sahm, I. Critchley, 2002, Journal of Clinical Microbiology.

Transferability andGenetic Relatedness ofHigh-Level Gentamicin Resistance amongEnterococci

D. Sahm, 1994 .

Multicenter Evaluation of the Acuitas AMR Gene Panel for Detection of an Extended Panel of Antimicrobial Resistance Genes among Bacterial Isolates

G. Walker, Y. Bergman, R. Yee, 2022, Journal of clinical microbiology.

Novel plasmid-mediated beta-lactamase (TEM-10) conferring selective resistance to ceftazidime and aztreonam in clinical isolates of Klebsiella pneumoniae

J. Quinn, K. Bush, D. Sahm, 1989, Antimicrobial Agents and Chemotherapy.

In Vitro Susceptibility of Global Surveillance Isolates of Pseudomonas aeruginosa to Ceftazidime-Avibactam (INFORM 2012 to 2014)

K. Kazmierczak, J. Karlowsky, D. Sahm, 2016, Antimicrobial Agents and Chemotherapy.

Results of the surveillance of Tedizolid activity and resistance program: in vitro susceptibility of gram-positive pathogens collected in 2011 and 2012 from the United States and Europe.

J. Deane, D. Sahm, Jeffrey B Locke, 2015, Diagnostic microbiology and infectious disease.

In vitro activity of ceftaroline against bacterial pathogens isolated from skin and soft tissue infections in Europe, Russia and Turkey in 2012: results from the Assessing Worldwide Antimicrobial Resistance Evaluation (AWARE) surveillance programme.

J. Karlowsky, D. Sahm, S. Bouchillon, 2016, The Journal of antimicrobial chemotherapy.

In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-β-lactamase-producing isolates (SIDERO-WT-2014 Study).

K. Kazmierczak, M. Hackel, R. Echols, 2019, International journal of antimicrobial agents.

Epidemiology and Antimicrobial Susceptibility of Gram-Negative Pathogens Causing Intra-abdominal Infections in Pediatric Patients in Europe—SMART 2011–2014

M. Hackel, D. Sahm, R. Badal, 2016, Journal of the Pediatric Infectious Diseases Society.

In vitro activities of various beta-lactam antimicrobial agents against clinical isolates of Escherichia coli and Klebsiella spp. resistant to oxyimino cephalosporins

R. Reichley, T. Bailey, D. Sahm, 1995, Antimicrobial agents and chemotherapy.

In vitro activity of ceftolozane/tazobactam against phenotypically defined extended-spectrum β-lactamase (ESBL)-positive isolates of Escherichia coli and Klebsiella pneumoniae isolated from hospitalized patients (SMART 2016).

K. Kazmierczak, M. Motyl, J. Karlowsky, 2019, Diagnostic microbiology and infectious disease.

Activity of Ertapenem against Enterobacteriaceae in seven global regions—SMART 2012–2016

M. Hackel, M. Motyl, D. Hoban, 2018, European Journal of Clinical Microbiology & Infectious Diseases.

Activity of Ertapenem against Enterobacteriaceae in seven global regions—SMART 2012–2016

M. Hackel, M. Motyl, D. Hoban, 2018, European Journal of Clinical Microbiology & Infectious Diseases.

In Vitro Activity of Cefepime-Taniborbactam and Comparators against Clinical Isolates of Gram-Negative Bacilli from 2018 to 2020: Results from the Global Evaluation of Antimicrobial Resistance via Surveillance (GEARS) Program

D. Daigle, M. Hackel, J. Karlowsky, 2022, Antimicrobial agents and chemotherapy.

Reduced susceptibility mechanism to cefiderocol, a siderophore cephalosporin, among clinical isolates from global surveillance program (SIDERO-WT-2014).

M. Hackel, D. Sahm, Naoki Kohira, 2020, Journal of global antimicrobial resistance.

Reproducibility of broth microdilution MICs for the novel siderophore cephalosporin, cefiderocol, determined using iron-depleted cation-adjusted Mueller-Hinton broth.

M. Hackel, J. Karlowsky, R. Echols, 2019, Diagnostic microbiology and infectious disease.

In Vitro Activity of Cefiderocol, a Siderophore Cephalosporin, Against Gram-Negative Bacilli Isolated by Clinical Laboratories in North America and Europe in 2015-2016: SIDERO-WT-2015.

M. Hackel, J. Karlowsky, R. Echols, 2019, International journal of antimicrobial agents.

Stratified analysis of multidrug-resistant Escherichia coli in US health care institutions.

A. Evangelista, D. Sahm, N. Brown, 2008, Postgraduate medicine.

Trends in Ciprofloxacin Nonsusceptibility and Levofloxacin Resistance among Streptococcus pneumoniae Isolates in North America

J. Karlowsky, M. Jones, D. Sahm, 2001, Journal of Clinical Microbiology.

The FDA Reboot of Antibiotic Development

B. Spellberg, D. Shlaes, D. Sahm, 2013, Antimicrobial Agents and Chemotherapy.

Effects of amino acids on expression of enterococcal vancomycin resistance

M. Gilmore, D. Sahm, L. Zarlenga, 1992, Antimicrobial Agents and Chemotherapy.

Current antimicrobial resistance profiles among methicillin-resistant Staphylococcus aureus encountered in the outpatient setting.

D. Sahm, Deborah C. Draghi, P. Hogan, 2006, Diagnostic microbiology and infectious disease.

Antimicrobial resistance trends among sinus isolates of Streptococcus pneumoniae in the United States (2001–2005)

A. Evangelista, M. Benninger, D. Sahm, 2007, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

Clostridium difficile culture-positive toxin-negative diarrhea.

S. Hanauer, D. Sahm, B. Lashner, 1986, The American journal of gastroenterology.

Activities of Newer Quinolones against Escherichia coli and Klebsiella pneumoniae Containing the Plasmid-Mediated Quinolone Resistance Determinant qnr

G. Jacoby, D. Hooper, D. Sahm, 2004, Antimicrobial Agents and Chemotherapy.

Activity of ceftolozane/tazobactam and imipenem/relebactam against clinical gram-negative isolates from Czech Republic, Hungary, and Poland—SMART 2017–2020

M. Motyl, D. Sahm, S. Hawser, 2023, European Journal of Clinical Microbiology & Infectious Diseases.

In vitro activity of imipenem-relebactam against resistant phenotypes of Enterobacteriaceae and Pseudomonas aeruginosa isolated from intraabdominal and urinary tract infection samples - SMART Surveillance Europe 2015-2017.

M. Motyl, J. Karlowsky, D. Sahm, 2020, Journal of medical microbiology.

Antimicrobial resistance and resistance mechanisms of Enterobacteriaceae in ICU and non-ICU wards in Europe and North America: SMART 2011-2013.

K. Kazmierczak, D. Sahm, R. Badal, 2015, Journal of global antimicrobial resistance.

1360. Antimicrobial Activity of Cefepime in Combination with VNRX-5133 Against a Global Collection of Enterobacteriaceae Including Resistant Phenotypes

D. Sahm, M. Hackel, 2018, Open Forum Infectious Diseases.

β-lactam antibiotics: The extended spectrum penicillins

R. Jones, D. Sahm, C. Thornsberry, 1985 .

Activity of imipenem/relebactam against Gram-negative bacilli from global ICU and non-ICU wards: SMART 2015-2016.

M. Motyl, D. Hoban, D. Sahm, 2018, Journal of global antimicrobial resistance.

Factors influencing fluoroquinolone resistance.

J. Karlowsky, D. Sahm, Mark E. Jones, 2003, Emerging infectious diseases.

In Vitro Activity of Iclaprim against Methicillin-Resistant Staphylococcus aureus Nonsusceptible to Daptomycin, Linezolid, or Vancomycin: A Pilot Study

D. Sahm, S. Hawser, C. Gemmell, 2017, The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale.

International Surveillance of Susceptibility to Levofloxacin and Other Agents among Respiratory Pathogens

M. Jones, D. Sahm, I. Critchley, 1999, Drugs.

Susceptibility of Staphylococcus aureus isolated from skin and wound infections in the United States 2005-07: laboratory-based surveillance study.

G. Tillotson, D. Sahm, I. Critchley, 2008, The Journal of antimicrobial chemotherapy.

Activity of cefditoren against beta-lactamase-positive and -negative Haemophilus influenzae and Moraxella catarrhalis.

J. Karlowsky, D. Sahm, I. Critchley, 2002, Diagnostic microbiology and infectious disease.

In Vitro activities of Tedizolid and comparator antimicrobial agents against clinical isolates of Staphylococcus aureus collected in 12 countries from 2014 to 2016.

M. Hackel, J. Karlowsky, D. Sahm, 2017, Diagnostic microbiology and infectious disease.

Comparative in vitro activities of ceftaroline and ceftriaxone against bacterial pathogens associated with respiratory tract infections: results from the AWARE surveillance study.

D. Sahm, D. Biedenbach, J. Iaconis, 2016, The Journal of antimicrobial chemotherapy.

Surveillance of tedizolid activity and resistance: In vitro susceptibility of Gram-positive pathogens collected over 5 years from the United States and Europe.

D. Sahm, M. Bensaci, 2017, Diagnostic microbiology and infectious disease.

Antimicrobial susceptibility profiles among common respiratory tract pathogens: a GLOBAL perspective.

D. Sahm, Mark E. Jones, C. Thornsberry, 2008, Postgraduate medicine.

In vitro activity of tedizolid against Staphylococcus aureus and Streptococcus pneumoniae collected in 2013 and 2014 from sites in Latin American countries, Australia, New Zealand, and China

D. Sahm, J. Alder, S. Bouchillon, 2016, European Journal of Clinical Microbiology & Infectious Diseases.

In Vitro Activity of Imipenem-Relebactam against Clinical Isolates of Gram-Negative Bacilli Isolated in Hospital Laboratories in the United States as Part of the SMART 2016 Program

K. Kazmierczak, M. Motyl, J. Karlowsky, 2018, Antimicrobial Agents and Chemotherapy.

Effect of Polysorbate-80 on Oritavancin Binding to Plastic Surfaces - 1

D. Sahm, G. Moeck, F. Arhin, 2008 .

Activity of imipenem/relebactam against Pseudomonas aeruginosa with antimicrobial-resistant phenotypes from seven global regions: SMART 2015-2016.

M. Motyl, J. Karlowsky, D. Sahm, 2018, Journal of global antimicrobial resistance.

Identification and Characterization of Linezolid-Resistant cfr-Positive Staphylococcus aureus USA300 Isolates from a New York City Medical Center

R. Goering, S. Jenkins, J. Deane, 2014, Antimicrobial Agents and Chemotherapy.

Detection of vancomycin-intermediate Staphylococcus aureus with the updated Trek-Sensititre System and the MicroScan System. Comparison with results from the conventional Etest and CLSI standardized MIC methods.

D. Sahm, Catherine Liu, Rohan Nadarajah, 2010, American journal of clinical pathology.

In Vitro Activity of Linezolid against Key Gram-Positive Organisms Isolated in the United States: Results of the LEADER 2004 Surveillance Program

D. Sahm, D. Sheehan, Deborah C. Draghi, 2005, Antimicrobial Agents and Chemotherapy.

Impact of Delays between Clinical and Laboratory Standards Institute and Food and Drug Administration Revisions of Interpretive Criteria for Carbapenem-Resistant Enterobacteriaceae

Kim F. Wong, Bruce Y. Lee, J. Jernigan, 2016, Journal of Clinical Microbiology.

In Vitro Activity of Tigecycline against Gram-Positive and Gram-Negative Pathogens as Evaluated by Broth Microdilution and Etest (cid:1)

D. Sahm, Deborah C. Draghi, M. Dowzicky, 2008 .

In Vitro Activity of Ceftaroline against Bacterial Pathogens Isolated from Patients with Skin and Soft Tissue and Respiratory Tract Infections in the Middle East and Africa: AWARE Global Surveillance Program 2015-2018.

M. Hackel, J. Karlowsky, D. Sahm, 2020, Journal of global antimicrobial resistance.

In vitro activity of Ceftaroline against bacterial pathogens isolated from patients with skin and soft tissue and respiratory tract infections in African and Middle Eastern countries: AWARE global surveillance program 2012-2014.

M. Hackel, J. Karlowsky, D. Sahm, 2016, Diagnostic microbiology and infectious disease.

Activity of ceftaroline and comparators against pathogens isolated from skin and soft tissue infections in Latin America – results of AWARE surveillance 2012

D. Hoban, D. Sahm, D. Biedenbach, 2015, The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases.

In vitro activity of oritavancin and comparator agents against staphylococci, streptococci and enterococci from clinical infections in Europe and North America, 2011-2014.

D. Sahm, G. Moeck, F. Arhin, 2015, International journal of antimicrobial agents.

Prevalence of Oxacillin Resistance in Staphylococcus aureus among Inpatients and Outpatients in the United States during 2000

J. Karlowsky, D. Sahm, Mark E. Jones, 2002, Antimicrobial Agents and Chemotherapy.

Multicenter Performance Assessment of Carba NP Test

Robin Patel, J. Mandrekar, R. Humphries, 2017, Journal of Clinical Microbiology.

Antimicrobial susceptibility of Gram‐negative ESKAPE pathogens isolated from hospitalized patients with intra‐abdominal and urinary tract infections in Asia‐Pacific countries: SMART 2013‐2015

M. Hackel, J. Karlowsky, D. Hoban, 2017, Journal of medical microbiology.

Antimicrobial Resistance among Respiratory Pathogens Collected in Thailand during 1999-2000

A. Vibhagool, J. Karlowsky, D. Sahm, 2002, Journal of chemotherapy.

Correlation of β-Lactamase Production and Colistin Resistance among Enterobacteriaceae Isolates from a Global Surveillance Program

K. Kazmierczak, M. Hackel, P. Bradford, 2015, Antimicrobial Agents and Chemotherapy.

Clinical and Public Health Implications of Macrolide-Resistant Streptococcus pneumoniae.

T. File, J. Metlay, M. Edmond, 2002, Journal of chemotherapy.

In vitro activity of imipenem-relebactam against Enterobacteriaceae and Pseudomonas aeruginosa isolated from intraabdominal and urinary tract infection samples - SMART Surveillance United States 2015-2017.

K. Kazmierczak, M. Motyl, J. Karlowsky, 2019, Journal of global antimicrobial resistance.

In Vitro Activity of Ceftolozane-Tazobactam, Imipenem-Relebactam, Ceftazidime-Avibactam, and Comparators against Pseudomonas aeruginosa Isolates Collected in United States Hospitals According to Results from the SMART Surveillance Program, 2018 to 2020

D. Hilbert, M. Motyl, J. Karlowsky, 2022, Antimicrobial agents and chemotherapy.

Pathogen Prevalence and Antimicrobial Susceptibility Among Enterobacteriaceae Causing Hospital-associated Intra-abdominal Infections in Adults in the United States (2012-2013).

M. Motyl, D. Sahm, R. Badal, 2016, Clinical therapeutics.

In vitro studies evaluating the activity of imipenem in combination with relebactam against Pseudomonas aeruginosa

D. Wisniewski, M. Motyl, N. Murgolo, 2019, BMC Microbiology.

Activity of Ceftolozane-Tazobactam and Comparators against Pseudomonas aeruginosa from Patients in Different Risk Strata -- SMART United States 2016-2017.

M. Motyl, D. Hoban, D. Sahm, 2020, Journal of global antimicrobial resistance.

1273. Activity of Ceftolozane/Tazobactam and Comparators Against Enterobacterales and P. aeruginosa Isolates from Pediatric Patients—SMART United States 2017-2019

M. Hackel, M. Motyl, D. Sahm, 2021, Open Forum Infectious Diseases.

Incidence of ESBLs and carbapenemases among Enterobacterales and carbapenemases in Pseudomonas aeruginosa isolates collected globally: results from ATLAS 2017-2019.

A. Gales, D. Sahm, M. Wise, 2023, The Journal of antimicrobial chemotherapy.

1066. In Vitro and in Vivo Antimicrobial Activity of Cefiderocol and Comparators against Achromobacter spp

D. Sahm, R. Nakai, Rio Nakamura, 2021, Open Forum Infectious Diseases.

1058. In Vitro and In Vivo Antibacterial Activity of Cefiderocol against Burkholderia spp

D. Sahm, Rio Nakamura, Y. Yamano, 2021, Open Forum Infectious Diseases.

1252. In Vitro Activity of Cefiderocol Against Metallo-β-Lactamase-Producing Gram-Negative Bacteria Collected in North America and Europe Between 2014 and 2017: SIDERO-WT-2014–2016 Studies

K. Kazmierczak, R. Echols, D. Sahm, 2020, Open Forum Infectious Diseases.

679. In vitro Activity of Cefiderocol (CFDC), a Novel Siderophore Cephalosporin, Against Difficult-to-Treat-Resistant (DTR) Gram-Negative Bacterial Pathogens From the Multi-National Sentinel Surveillance Study, SIDERO-WT (2014–2017)

D. Sahm, M. Tsuji, Y. Yamano, 2019, Open Forum Infectious Diseases.

1452. Molecular Profile of β-Lactamase Genes and Siderophore-Dependent Iron Transporter Genes of Cefiderocol High MIC Isolates from SIDERO-WT Studies

K. Kazmierczak, R. Echols, D. Sahm, 2020 .

Invitro activity of imipenem-relebactam against gram-negative bacilli isolated from patients with lower respiratory tract infections in the United States in 2015 - Results from the SMART global surveillance program.

K. Kazmierczak, M. Hackel, M. Motyl, 2017, Diagnostic microbiology and infectious disease.

Comparison oftheAutoSCAN-W/A RapidBacterial Identification SystemandtheVitek AutoMicrobic Systemfor Identification ofGram-Negative Bacilli

D. Rhoden, M. Pfaller, D. Sahm, 1991 .

In Vitro Activity of Imipenem/Relebactam Against Gram-Negative Bacilli from Pediatric Patients-Study for Monitoring Antimicrobial Resistance Trends (SMART) global surveillance program 2015-2017.

M. Motyl, J. Karlowsky, D. Sahm, 2020, Journal of the Pediatric Infectious Diseases Society.

Pharmacodynamic evaluation of i.v. antimicrobials against Pseudomonas aeruginosa samples collected from U.S. hospitals.

D. Nicolau, D. Sahm, J. Kuti, 2011, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

Reliability of the E test for detection of ampicillin, vancomycin, and high-level aminoglycoside resistance in Enterococcus spp

D. Sahm, J. E. Schulz, 1993, Journal of clinical microbiology.

The Activity of Levofloxacin and Comparator Agents against Clinical Isolates of Streptococcus pneumoniae Collected Worldwide during 1999 and 2000

J. Karlowsky, D. Sahm, I. Critchley, 2002, Chemotherapy.

Baseline in vitro Activity of Tigecycline among Key Bacterial Pathogens Exhibiting Multidrug Resistance

D. Sahm, Deborah C. Draghi, M. Dowzicky, 2008, Chemotherapy.

Proficiency of Italian clinical laboratories in detecting reduced glycopeptide susceptibility in Enterococcus and Staphylococcus spp. using routine laboratory methodologies.

A. Goglio, D. Sahm, G. Gesu, 2002, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

In Vitro Activity of AZD0914, a Novel Bacterial DNA Gyrase/Topoisomerase IV Inhibitor, against Clinically Relevant Gram-Positive and Fastidious Gram-Negative Pathogens

M. Huband, M. Hackel, P. Bradford, 2015, Antimicrobial Agents and Chemotherapy.

In vitro activity of imipenem/relebactam against non-Morganellaceae Enterobacterales and Pseudomonas aeruginosa in the Asia-Pacific region: SMART 2017-2020.

M. Motyl, J. Karlowsky, D. Sahm, 2023, International Journal of Antimicrobial Agents.

High-level gentamicin resistance among enterococci.

M. Gilmore, D. Sahm, 1995, Developments in biological standardization.

Heterogeneous expression of glycopeptide resistance in enterococci associated with transfer of vanB

D. Sahm, M. Hayden, R. Picken, 1997, Antimicrobial agents and chemotherapy.

Erratum for Karlowsky et al., “In Vitro Susceptibility of Gram-Negative Pathogens to Cefiderocol in Five Consecutive Annual Multinational SIDERO-WT Surveillance Studies, 2014 to 2019”

M. Hackel, J. Karlowsky, R. Echols, 2023, Antimicrobial Agents and Chemotherapy.

Mycobacterium marinum infection confused with sporotrichosis

D. Sahm, J. Lloyd, P. Revis, 1985 .

In Vitro Activity of Ceftibuten-Avibactam against β-Lactamase-Positive Enterobacterales from the ATLAS Global Surveillance Program

M. Hackel, J. Karlowsky, D. Sahm, 2023, Antimicrobial agents and chemotherapy.

Susceptibility profile and β-lactamase content of global Pseudomonas aeruginosa isolates resistant to ceftolozane/tazobactam and/or imipenem/relebactam—SMART 2016–21

M. Motyl, J. Karlowsky, D. Sahm, 2023, JAC-antimicrobial resistance.

Annals of Clinical Microbiology and Antimicrobials Laboratory-based Surveillance of Current Antimicrobial Resistance Patterns and Trends among Staphylococcus Aureus: 2005 Status in the United States

D. Sahm, D. Sheehan, P. Hogan, 2022 .

Annals of Clinical Microbiology and Antimicrobials Open Access Prevalence and Antimicrobial Susceptibilities of Bacteria Isolated from Blood Cultures of Hospitalized Patients in the United States in 2002

J. Karlowsky, D. Sahm, Mark E. Jones, 2004 .

In vitro activity of levofloxacin against contemporary clinical isolates of Legionella pneumophila, Mycoplasma pneumoniae and Chlamydia pneumoniae from North America and Europe.

A. Evangelista, J. Karlowsky, M. Jones, 2002, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Multiple-drug resistant enterococci: the nature of the problem and an agenda for the future.

M. Gilmore, D. Sahm, M. Huycke, 1998, Emerging infectious diseases.

Resistance issues and community-acquired respiratory infections.

D. Sahm, 2003, Clinical cornerstone.

In Vitro Susceptibility to Ceftazidime-Avibactam of Carbapenem-Nonsusceptible Enterobacteriaceae Isolates Collected during the INFORM Global Surveillance Study (2012 to 2014)

K. Kazmierczak, J. Karlowsky, D. Sahm, 2016, Antimicrobial Agents and Chemotherapy.

In Vitro Activity of Aztreonam-Avibactam against a Global Collection of Gram-Negative Pathogens from 2012 and 2013

K. Kazmierczak, P. Bradford, D. Sahm, 2015, Antimicrobial Agents and Chemotherapy.

J. Karlowsky, D. Sahm, M. Wikler, 2008 .

Factors influencing fluoroquinolone resistance.

J. Karlowsky, D. Sahm, Mark E. Jones, 2003, Emerging infectious diseases.

Increasing role of Staphylococcus aureus and community-acquired methicillin-resistant Staphylococcus aureus infections in the United States: a 10-year trend of replacement and expansion.

C. Hogea, C. Acosta, J. Suaya, 2011, Microbial drug resistance.

In Vitro Activity of Ceftaroline against Staphylococcus aureus Isolated in 2012 from Asia-Pacific Countries as Part of the AWARE Surveillance Program

J. Ambler, R. Alm, D. Hoban, 2015, Antimicrobial Agents and Chemotherapy.